Previous genetic research in pediatric cardiomyopathy (CM) has focused on pathogenic variants for diagnostic purposes, with limited data evaluating genotype-outcome correlations. We explored whether greater genetic variant burden (pathogenic or variants of unknown significance, VUS) correlates with worse outcomes.
Children with dilated CM (DCM) and hypertrophic CM (HCM) who underwent multigene testing between 2010 and 2018 were included. Composite endpoint was freedom from major adverse cardiac event (MACE).
Three hundred and thirty-eight subjects were included [49% DCM, median age 5.7 (interquartile range (IQR) 0.2–13.4) years, 51% HCM, median age 3.0 (IQR 0.1–12.5) years]. Pathogenic variants alone were not associated with MACE in either cohort (DCM p = 0.44; HCM p = 0.46). In DCM, VUS alone [odds ratio (OR) 4.0, 95% confidence interval (CI) 1.9–8.3] and in addition to pathogenic variants (OR 5.2, 95% CI 1.7–15.9) was associated with MACE. The presence of VUS alone or in addition to pathogenic variants were not associated with MACE in HCM (p = 0.22 and p = 0.33, respectively).
Increased genetic variant burden (pathogenic variants and VUS) is associated with worse clinical outcomes in DCM but not HCM. Genomic variants that influence DCM onset may be distinct from those driving disease progression, highlighting the potential value of universal genetic testing to improve risk stratification.
In pediatric CM, inconsistent findings historically have been shown between genotype and phenotype severity when only pathogenic variants have been considered.
Increased genetic variant burden (including both pathogenic variants and VUS) is associated with worse clinical outcomes in DCM but not HCM.
Genomic variants that influence CM onset may be distinct from those variants that drive disease progression and influence outcomes in phenotype-positive individuals.
Incorporation of both pathogenic variants and VUS may improve risk stratification models in pediatric CM.
Subscribe to Journal
Get full journal access for 1 year
only $38.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lipshultz, S. E. et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 348, 1647–1655 (2003).
Lee, T. M. et al. Pediatric cardiomyopathies. Circ. Res. 121, 855–873 (2017).
Pugh, T. J. et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet. Med. 16, 601–608 (2014).
Fatkin, D. et al. Precision medicine in the management of dilated cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 2921–2938 (2019).
Herkert, J. C. et al. Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genet. Med. 20, 1374–1386 (2018).
Vasilescu, C. et al. Genetic basis of severe childhood-onset cardiomyopathies. J. Am. Coll. Cardiol. 72, 2324–2338 (2018).
Kuhnisch, J. et al. Targeted panel sequencing in pediatric primary cardiomyopathy supports a critical role of TNNI3. Clin. Genet. 96, 549–559 (2019).
Cuenca, S. et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J. Heart Lung Transplant. 35, 625–635 (2016).
Morita, H. et al. Shared genetic causes of cardiac hypertrophy in children and adults. N. Engl. J. Med. 358, 1899–1908 (2008).
Kantor Paul, F. et al. Abstract 14210: phenotype, but not genotype, determines survival in pediatric dilated cardiomyopathy: a study from the NHLBI-Funded Pediatric Cardiomyopathy Registry. Circulation 138(Suppl_1), A14210–A14210 (2018).
Limongelli, G. et al. Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. J. Cardiovasc. Med. (Hagerstown) 18, 249–254 (2017).
Mathew, J. et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin. Genet. 93, 310–319 (2018).
Al-Wakeel-Marquard, N. et al. RIKADA study reveals risk factors in pediatric primary cardiomyopathy. J. Am. Heart Assoc. 8, e012531 (2019).
Kim, D. S. et al. Patient genotypes impact survival after surgery for isolated congenital heart disease. Ann. Thorac. Surg. 98, 104–110 (2014). discussion 110–1.
Kim, D. S. et al. Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. J. Thorac. Cardiovasc. Surg. 151, 1147–51 e4 (2016).
Blue, G. M. et al. Genetic burden and associations with adverse neurodevelopment in neonates with congenital heart disease. Am. Heart J. 201, 33–39 (2018).
Lipshultz, S. E. et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American Heart Association. Circulation 140, e9–e68 (2019).
Kampmann, C. et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart 83, 667–672 (2000).
Grenier, M. A. et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am. Heart J. 139(Part 3), S86–S95 (2000).
Lopez, L. et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J. Am. Soc. Echocardiogr. 23, 465–495 (2010). quiz 576-7.
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Hershberger, R. E. et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 20, 899–909 (2018).
Kindel, S. J. et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J. Card. Fail. 18, 396–403 (2012).
Ellepola, C. D. et al. Genetic testing in pediatric cardiomyopathy. Pediatr. Cardiol. 39, 491–500 (2018).
Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224 (2018).
Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19, 581–590 (2018).
This work was supported, in part, by the Cardiac Center Clinical Research Core at the Children’s Hospital of Philadelphia. No specific support was provided for this project.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Burstein, D.S., Gaynor, J.W., Griffis, H. et al. Genetic variant burden and adverse outcomes in pediatric cardiomyopathy. Pediatr Res (2020). https://doi.org/10.1038/s41390-020-1101-5